Opportunities for Use of Human iPS Cells in Predictive Toxicology
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Toxicity assessment is a major challenge in cost-effective drug development, and there is a great need for better tools to accurately predict adverse drug reactions. Technological advances are empowering new cell-based assays for predictive toxicology, and these assays are critically dependent on the cell source. Here, we describe the properties of human induced pluripotent stem (iPS) cells that make them a promising source for toxicity assessment, highlight the progress to date, and point out the important roadblocks that remain. Clinical Pharmacology & Therapeutics (2011) 89 5, 754–758. doi:10.1038/clpt.2011.9
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
He, J.-Q., Ma, Y., Lee, Y., Thomson, J. A., & Kamp, T. J. (2003) · Circulation Research · doi:10.1161/01.res.0000080317.92718.99 · Cited by 800
Self-citationHuman hepatocytes as a tool for studying toxicity and drug metabolism
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489424 · Cited by 242
Cited by
Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J., Kolaja, K. L., Swanson, B. J., & January, C. T. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00694.2011 · Cited by 770
Self-citationThe Adverse Effects of Air Pollution on the Nervous System
Genc, S., Zadeoglulari, Z., Fuss, S. H., & Genc, K. (2012) · Journal of Toxicology · doi:10.1155/2012/782462 · Cited by 717
Mummery, C. L., Zhang, J., Ng, E. S., Elliott, D. A., Elefanty, A. G., & Kamp, T. J. (2012) · Circulation Research · doi:10.1161/circresaha.110.227512 · Cited by 713
Self-citationDrug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Herron, T. J., Rocha, A. M. D., Campbell, K. F., Ponce-Balbuena, D., Willis, B. C., Guerrero-Serna, G., Liu, Q., Klos, M., Musa, H., Zarzoso, M., et al. (2016) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.113.003638 · Cited by 257
“1 The generation of induced human pluripotent stem cell– derived cardiomyocytes (hPSC-CMs) offers a revolutionary platform to study physiological/pathophysiological processes and cardiac arrhythmia mechanisms and for the development of new therapies in vitro.(1,2) Experimentally, they offer a human system that can be…”
BackgroundCompetency of different cell models to predict human hepatotoxic drugs
Gómez-Lechón, M. J., Tolosa, L., Conde, I., & Donato, M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967680 · Cited by 199
“Specifically, iPSC-hepatocytes generated from individuals with different CYP polymorphisms would be of great value for the drug metabolism and toxicity prediction of new drugs in pre-clinical stages to enable more successful clinical trials [99,102,105].”
BackgroundModels of Drug Induced Liver Injury (DILI)—Current Issues and Future Perspectives
Kuna, L., Bozic, I., Kizivat, T., Bojanic, K., Mrso, M., Kralj, E., Smolic, R., Wu, G. Y., & Smolic, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180523095355 · Cited by 127
De Masi, C., Spitalieri, P., Murdocca, M., Novelli, G., & Sangiuolo, F. (2020) · Human Genomics · doi:10.1186/s40246-020-00276-2 · Cited by 91
Benesic, A., Leitl, A., & Gerbes, A. L. (2016) · Gut · doi:10.1136/gutjnl-2015-309528 · Cited by 48
Prediction of developmental chemical toxicity based on gene networks of human embryonic stem cells
Yamane, J., Aburatani, S., Imanishi, S., Akanuma, H., Nagano, R., Kato, T., Sone, H., Ohsako, S., & Fujibuchi, W. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw450 · Cited by 37
“(57), human iPS cells and their derivatives, such as tissues and organs, are a promising resource for toxicity assessment.”
Jiang, X., Lian, X., Wei, K., Zhang, J., Yu, K., Li, H., Ma, H., Cai, Y., & Pang, L. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03961-4 · Cited by 23
Sirenko, O., Hancock, M. K., Crittenden, C., Hammer, M., Keating, S., Carlson, C. B., & Chandy, G. (2017) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2017.792 · Cited by 20
Metadata
- Authors
- Anson, B. D., Kolaja, K. L., & Kamp, T. J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-03-23
- Volume
- 89
- Issue
- 5
- Pages
- 754-758
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2008446011
- Cited by
- 145
- References
- 7
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.